GPC3-IL7-CCL19-CAR-T Primes Immune Microenvironment Reconstitution for Hepatocellular Carcinoma Therapy

Investigators engineered a novel GPC3-targeting CAR including an anti-GPC3 scFv, CD3ζ, CD28, and 4-1BB that induced co-expression of IL-7 at a moderate level and CCL19 at a high level, and transduced it into human T cells.